Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Colorectal Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 164 articles: HTML format

Single Articles

April 2024
1. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
   Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
   Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667.
   PubMed    
   
   
   
2. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
   Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
   Br J Cancer. 2024;130:1059-1072.
   PubMed     Abstract available
   
   
   
3. TIAN Y, Lin Y, Qu C, Arndt V, et al
   Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
   Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
   PubMed     Abstract available
   
   
   March 2024
4. FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al
   Functional proteomics of colon cancer Consensus Molecular Subtypes.
   Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650.
   PubMed     Abstract available
   
   
   
5. ZHANG X, He Y, Li X, Shraim R, et al
   Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation.
   Br J Cancer. 2024 Mar 13. doi: 10.1038/s41416-024-02643.
   PubMed     Abstract available
   
   
   
6. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
   Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
   Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02649.
   PubMed     Abstract available
   
   
   
7. DENG LQ, Shi CJ, Zhou ST, Zeng WQ, et al
   EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis.
   Br J Cancer. 2024 Mar 8. doi: 10.1038/s41416-024-02612.
   PubMed     Abstract available
   
   
   
8. GOURIOU C, Lemanski C, Pommier P, Le Malicot K, et al
   Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
   Br J Cancer. 2024;130:769-776.
   PubMed     Abstract available
   
   
   February 2024
9. KARAPETIS CS, Liu H, Sorich MJ, Pederson LD, et al
   Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials fro
   Br J Cancer. 2024 Feb 24. doi: 10.1038/s41416-024-02604.
   PubMed     Abstract available
   
   
   
10. PRETE AA, Angerilli V, Bergamo F, Vettore V, et al
    HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-023-02569.
    PubMed     Abstract available
    
    
    
11. HSIEH HH, Chen CL, Chan HW, Chi KH, et al
    Enhanced antitumour response of gold nanostar-mediated photothermal therapy in combination with immunotherapy in a mouse model of colon carcinoma.
    Br J Cancer. 2024;130:406-416.
    PubMed     Abstract available
    
    
    
12. FLECCHIA C, Auclin E, Alouani E, Mercier M, et al
    Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study.
    Br J Cancer. 2024;130:442-449.
    PubMed     Abstract available
    
    
    January 2024
13. SHAH ET, Molloy C, Gough M, Kryza T, et al
    Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells.
    Br J Cancer. 2024 Jan 29. doi: 10.1038/s41416-024-02584.
    PubMed     Abstract available
    
    
    
14. FATIMA I, Ahmad R, Barman S, Gowrikumar S, et al
    Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20.
    Br J Cancer. 2024 Jan 26. doi: 10.1038/s41416-023-02570.
    PubMed     Abstract available
    
    
    
15. XIAO H, Weng Z, Sun K, Shen J, et al
    Predicting 5-year recurrence risk in colorectal cancer: development and validation of a histology-based deep learning approach.
    Br J Cancer. 2024 Jan 20. doi: 10.1038/s41416-024-02573.
    PubMed     Abstract available
    
    
    
16. CHEN M, Liu H, Liang W, Huang P, et al
    Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
    Br J Cancer. 2024 Jan 13. doi: 10.1038/s41416-023-02568.
    PubMed     Abstract available
    
    
    
17. JOO JE, Chu YL, Georgeson P, Walker R, et al
    Intratumoral presence of the genotoxic gut bacteria pks(+) E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer.
    Br J Cancer. 2024 Jan 10. doi: 10.1038/s41416-023-02554.
    PubMed     Abstract available
    
    
    
18. CONTRERAS-TOLEDO D, Jimenez-Fonseca P, Lopez CL, Montes AF, et al
    Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
    Br J Cancer. 2024 Jan 8. doi: 10.1038/s41416-023-02563.
    PubMed     Abstract available
    
    
    
19. TAMLANDER M, Jermy B, Seppala TT, Farkkila M, et al
    Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening.
    Br J Cancer. 2024 Jan 3. doi: 10.1038/s41416-023-02536.
    PubMed     Abstract available
    
    
    
20. WATTS EL, Gonzales TI, Strain T, Saint-Maurice PF, et al
    Observational and genetic associations between cardiorespiratory fitness and cancer: a UK Biobank and international consortia study.
    Br J Cancer. 2024;130:114-124.
    PubMed     Abstract available
    
    
    
21. LING S, Luque Fernandez MA, Quaresma M, Belot A, et al
    Inequalities in treatment among patients with colon and rectal cancer: a multistate survival model using data from England national cancer registry 2012-2016.
    Br J Cancer. 2024;130:88-98.
    PubMed     Abstract available
    
    
    December 2023
22. KIM S, Lee DH, Giovannucci EL, Keum N, et al
    Association between weight cycling and risk of colorectal cancer: a prospective cohort study.
    Br J Cancer. 2023 Dec 19. doi: 10.1038/s41416-023-02529.
    PubMed     Abstract available
    
    
    
23. LIU B, Wu T, Lin B, Liu X, et al
    Periostin-TGF-beta feedforward loop contributes to tumour-stroma crosstalk in liver metastatic outgrowth of colorectal cancer.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02516.
    PubMed     Abstract available
    
    
    
24. STROUS MTA, Molenaar CJL, Franssen RFW, van Osch F, et al
    Treatment interval in curative treatment of colon cancer, does it impact (cancer free) survival? A non-inferiority analysis.
    Br J Cancer. 2023 Dec 12. doi: 10.1038/s41416-023-02505.
    PubMed     Abstract available
    
    
    
25. KUCUKKOSE E, Baars MJD, Amini M, Schraa SJ, et al
    Stromal localization of inactive CD8(+) T cells in metastatic mismatch repair deficient colorectal cancer.
    Br J Cancer. 2023 Dec 2. doi: 10.1038/s41416-023-02500.
    PubMed     Abstract available
    
    
    
26. EDIN S, Gylling B, Li X, Stenberg A, et al
    Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer - possible implications for immunotherapy.
    Br J Cancer. 2023 Dec 1. doi: 10.1038/s41416-023-02483.
    PubMed     Abstract available
    
    
    November 2023
27. SCHMOLL HJ, Mann J, Meinert F, Garlipp B, et al
    Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
    Br J Cancer. 2023 Nov 23. doi: 10.1038/s41416-023-02496.
    PubMed     Abstract available
    
    
    
28. CHEN M, Mashima T, Oishi T, Muramatsu Y, et al
    APC/PIK3CA mutations and beta-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
    Br J Cancer. 2023 Nov 15. doi: 10.1038/s41416-023-02484.
    PubMed     Abstract available
    
    
    
29. GUAN X, Cheng P, Wei R, Li J, et al
    Enlarged tumour-draining lymph node with immune-activated profile predict favourable survival in non-metastatic colorectal cancer.
    Br J Cancer. 2023 Nov 13. doi: 10.1038/s41416-023-02473.
    PubMed     Abstract available
    
    
    
30. PRETTA A, Ziranu P, Giampieri R, Pinna G, et al
    Mismatch Repair system protein deficiency as a resistance factor for locally advanced rectal adenocarcinoma patients receiving neoadjuvant chemo-radiotherapy.
    Br J Cancer. 2023;129:1619-1624.
    PubMed     Abstract available
    
    
    
31. KOUKOURAKIS IM, Xanthopoulou E, Sgouras TI, Kouroupi M, et al
    Preoperative chemoradiotherapy induces multiple pathways related to anti-tumour immunity in rectal cancer.
    Br J Cancer. 2023;129:1852-1862.
    PubMed     Abstract available
    
    
    October 2023
32. TSAI HL, Lin CC, Sung YC, Chen SH, et al
    The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.
    Br J Cancer. 2023;129:947-955.
    PubMed     Abstract available
    
    
    
33. KOBAYASHI Y, Niida A, Nagayama S, Saeki K, et al
    Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers.
    Br J Cancer. 2023;129:1105-1118.
    PubMed     Abstract available
    
    
    
34. ZHAO M, Feng L, Zhao K, Cui Y, et al
    An MRI-based scoring system for pretreatment risk stratification in locally advanced rectal cancer.
    Br J Cancer. 2023;129:1095-1104.
    PubMed     Abstract available
    
    
    
35. THOMAS EM, Wright JA, Blake SJ, Page AJ, et al
    Advancing translational research for colorectal immuno-oncology.
    Br J Cancer. 2023;129:1442-1450.
    PubMed     Abstract available
    
    
    September 2023
36. SHI S, Wang K, Ugai T, Giannakis M, et al
    Vitamin C intake and colorectal cancer survival according to KRAS and BRAF mutation: a prospective study in two US cohorts.
    Br J Cancer. 2023 Sep 30. doi: 10.1038/s41416-023-02452.
    PubMed     Abstract available
    
    
    
37. DAY D, Park JJ, Coward J, Markman B, et al
    A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.
    Br J Cancer. 2023 Sep 20. doi: 10.1038/s41416-023-02431.
    PubMed     Abstract available
    
    
    
38. JOHARATNAM-HOGAN N, Hatem D, Cafferty FH, Petrucci G, et al
    Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.
    Br J Cancer. 2023;129:706-720.
    PubMed     Abstract available
    
    
    August 2023
39. ZHOU X, Xiao Q, Jiang F, Sun J, et al
    Dissecting the pathogenic effects of smoking and its hallmarks in blood DNA methylation on colorectal cancer risk.
    Br J Cancer. 2023 Aug 22. doi: 10.1038/s41416-023-02397.
    PubMed     Abstract available
    
    
    
40. MAGNUSSON MI, Agnarsson BA, Jonasson JG, Tryggvason T, et al
    Histopathology and levels of proteins in plasma associate with survival after colorectal cancer diagnosis.
    Br J Cancer. 2023 Aug 18. doi: 10.1038/s41416-023-02374.
    PubMed     Abstract available
    
    
    
41. BELLI S, Pesapane A, Servetto A, Esposito D, et al
    Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
    Br J Cancer. 2023 Aug 11. doi: 10.1038/s41416-023-02390.
    PubMed     Abstract available
    
    
    
42. HASHIMOTO T, Takayanagi D, Yonemaru J, Naka T, et al
    A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.
    Br J Cancer. 2023 Aug 5. doi: 10.1038/s41416-023-02382.
    PubMed     Abstract available
    
    
    
43. DROSDOWSKY A, Lamb KE, Karahalios A, Bergin RJ, et al
    The effect of time before diagnosis and treatment on colorectal cancer outcomes: systematic review and dose-response meta-analysis.
    Br J Cancer. 2023 Aug 1. doi: 10.1038/s41416-023-02377.
    PubMed     Abstract available
    
    
    July 2023
44. LEE SH, Pankaj A, Neyaz A, Ono Y, et al
    Immune microenvironment and lymph node yield in colorectal cancer.
    Br J Cancer. 2023 Jul 28. doi: 10.1038/s41416-023-02372.
    PubMed     Abstract available
    
    
    
45. ROS J, Salva F, Dopazo C, Lopez D, et al
    Correction To: Liver transplantation in metastatic colorectal cancer: are we ready for it?
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02370.
    PubMed    
    
    
    
46. KORTLEVER TL, van der Vlugt M, Duijkers FAM, Masclee A, et al
    Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme.
    Br J Cancer. 2023 Jul 19. doi: 10.1038/s41416-023-02358.
    PubMed     Abstract available
    
    
    
47. SAFIZADEH F, Mandic M, Pulte D, Niedermaier T, et al
    The underestimated impact of excess body weight on colorectal cancer risk: Evidence from the UK Biobank cohort.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02351.
    PubMed     Abstract available
    
    
    
48. BRENNE SS, Madsen PH, Pedersen IS, Hveem K, et al
    Colorectal cancer detected by liquid biopsy 2 years prior to clinical diagnosis in the HUNT study.
    Br J Cancer. 2023 Jul 12. doi: 10.1038/s41416-023-02337.
    PubMed     Abstract available
    
    
    
49. WATLING CZ, Kelly RK, Dunneram Y, Knuppel A, et al
    Associations of intakes of total protein, protein from dairy sources, and dietary calcium with risks of colorectal, breast, and prostate cancer: a prospective analysis in UK Biobank.
    Br J Cancer. 2023 Jul 5. doi: 10.1038/s41416-023-02339.
    PubMed     Abstract available
    
    
    June 2023
50. DIMOU N, Kim AE, Flanagan O, Murphy N, et al
    Probing the diabetes and colorectal cancer relationship using gene - environment interaction analyses.
    Br J Cancer. 2023 Jun 26. doi: 10.1038/s41416-023-02312.
    PubMed     Abstract available
    
    
    
51. REN JJ, Li ZH, Zhong WF, Chen PL, et al
    Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes.
    Br J Cancer. 2023 Jun 19. doi: 10.1038/s41416-023-02323.
    PubMed     Abstract available
    
    
    
52. RYOO SB, Heo S, Lim Y, Lee W, et al
    Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Br J Cancer. 2023 Jun 6. doi: 10.1038/s41416-023-02300.
    PubMed     Abstract available
    
    
    May 2023
53. LEE S, Ma C, Shi Q, Meyers J, et al
    Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance).
    Br J Cancer. 2023 May 13. doi: 10.1038/s41416-023-02290.
    PubMed     Abstract available
    
    
    
54. SOREIDE K
    Liver transplantation for non-resectable colorectal liver metastases: the thin red line.
    Br J Cancer. 2023;128:1794-1796.
    PubMed     Abstract available
    
    
    April 2023
55. KASTINEN M, Sirnio P, Elomaa H, Ahtiainen M, et al
    Immunological and prognostic significance of tumour necrosis in colorectal cancer.
    Br J Cancer. 2023 Apr 8. doi: 10.1038/s41416-023-02258.
    PubMed     Abstract available
    
    
    
56. ZHANG S, Hur J, Song R, Wang P, et al
    Adherence to the World Cancer Research Fund/American Institute for Cancer Research cancer prevention recommendations throughout the life course and risk of colorectal cancer precursors.
    Br J Cancer. 2023 Apr 7. doi: 10.1038/s41416-023-02255.
    PubMed     Abstract available
    
    
    
57. ISHINO T, Kawashima S, Tanji E, Ueno T, et al
    Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens.
    Br J Cancer. 2023;128:1166-1175.
    PubMed     Abstract available
    
    
    
58. KOSUMI K, Baba Y, Yamamura K, Nomoto D, et al
    Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer.
    Br J Cancer. 2023;128:1155-1165.
    PubMed     Abstract available
    
    
    March 2023
59. ELOMAA H, Ahtiainen M, Vayrynen SA, Ogino S, et al
    Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer.
    Br J Cancer. 2023 Mar 31. doi: 10.1038/s41416-023-02238.
    PubMed     Abstract available
    
    
    
60. ROS J, Salva F, Dopazo C, Lopez D, et al
    Liver transplantation in metastatic colorectal cancer: are we ready for it?
    Br J Cancer. 2023 Mar 6. doi: 10.1038/s41416-023-02213.
    PubMed     Abstract available
    
    
    
61. KUBOKI Y, Terazawa T, Masuishi T, Nakamura M, et al
    Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
    Br J Cancer. 2023 Mar 4. doi: 10.1038/s41416-023-02212.
    PubMed     Abstract available
    
    
    
62. KITAKAZE M, Uemura M, Hara T, Chijimatsu R, et al
    Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer.
    Br J Cancer. 2023 Mar 3. doi: 10.1038/s41416-023-02202.
    PubMed     Abstract available
    
    
    
63. ABILDGAARD AB, Nielsen SV, Bernstein I, Stein A, et al
    Lynch syndrome, molecular mechanisms and variant classification.
    Br J Cancer. 2023;128:726-734.
    PubMed     Abstract available
    
    
    February 2023
64. LI M, Zhu C, Xue Y, Miao C, et al
    A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal cancer.
    Br J Cancer. 2023 Feb 24. doi: 10.1038/s41416-023-02155.
    PubMed     Abstract available
    
    
    
65. JACOB J, Francisco LE, Chatterjee T, Liang Z, et al
    An antibody-drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02192.
    PubMed     Abstract available
    
    
    
66. PILLERON S, Maringe C, Morris EJA, Leyrat C, et al
    Immortal-time bias in older vs younger age groups: a simulation study with application to a population-based cohort of patients with colon cancer.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02187.
    PubMed     Abstract available
    
    
    
67. AGLAGO EK, Cross AJ, Riboli E, Fedirko V, et al
    Dietary intake of total, heme and non-heme iron and the risk of colorectal cancer in a European prospective cohort study.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02164.
    PubMed     Abstract available
    
    
    
68. MORETTO R, Germani MM, Giordano M, Conca V, et al
    Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
    Br J Cancer. 2023 Feb 9. doi: 10.1038/s41416-023-02180.
    PubMed     Abstract available
    
    
    
69. SEDLMEIER AM, Viallon V, Ferrari P, Peruchet-Noray L, et al
    Body shape phenotypes of multiple anthropometric traits and cancer risk: a multi-national cohort study.
    Br J Cancer. 2023;128:594-605.
    PubMed     Abstract available
    
    
    January 2023
70. AMIRKHAH R, Gilroy K, Malla SB, Lannagan TRM, et al
    MmCMS: mouse models' consensus molecular subtypes of colorectal cancer.
    Br J Cancer. 2023 Jan 30. doi: 10.1038/s41416-023-02157.
    PubMed     Abstract available
    
    
    
71. YAN H, Talty R, Aladelokun O, Bosenberg M, et al
    Ferroptosis in colorectal cancer: a future target?
    Br J Cancer. 2023 Jan 26. doi: 10.1038/s41416-023-02149.
    PubMed     Abstract available
    
    
    
72. KELLY ME, O'Sullivan NJ, Bolger JC, Polignano F, et al
    Age alone is not a barrier to efficacy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: analysis of 1138 patients from the UK and Ireland Colorectal Peritoneal Metastases Registry.
    Br J Cancer. 2023;128:42-47.
    PubMed     Abstract available
    
    
    
73. PAOLUCCI I, Lin YM, Kawaguchi Y, Maki H, et al
    Targeted exome-based predictors of patterns of progression of colorectal liver metastasis after percutaneous thermal ablation.
    Br J Cancer. 2023;128:130-136.
    PubMed     Abstract available
    
    
    
74. BILAL M, Nimir M, Snead D, Taylor GS, et al
    Role of AI and digital pathology for colorectal immuno-oncology.
    Br J Cancer. 2023;128:3-11.
    PubMed     Abstract available
    
    
    December 2022
75. BAKER KJ, Brint E, Houston A
    Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02083.
    PubMed     Abstract available
    
    
    
76. VILLEGER R, Chulkina M, Mifflin RC, Markov NS, et al
    Loss of alcohol dehydrogenase 1B in cancer-associated fibroblasts: contribution to the increase of tumor-promoting IL-6 in colon cancer.
    Br J Cancer. 2022 Dec 8. doi: 10.1038/s41416-022-02066.
    PubMed     Abstract available
    
    
    
77. ALEXANDER PG, van Wyk HC, Pennel KAF, Hay J, et al
    The Glasgow Microenvironment Score and risk and site of recurrence in TNM I-III colorectal cancer.
    Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02069.
    PubMed     Abstract available
    
    
    
78. MAES-CARBALLO M, Garcia-Garcia M, Martin-Diaz M, Estrada-Lopez CR, et al
    A comprehensive systematic review of colorectal cancer screening clinical practices guidelines and consensus statements.
    Br J Cancer. 2022 Dec 7. doi: 10.1038/s41416-022-02070.
    PubMed     Abstract available
    
    
    November 2022
79. KEANE JM, Walsh CJ, Cronin P, Baker K, et al
    Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints.
    Br J Cancer. 2022 Nov 23. doi: 10.1038/s41416-022-02062.
    PubMed     Abstract available
    
    
    
80. HONG XL, Yu TC, Huang XW, Wang JL, et al
    Metformin abrogates Fusobacterium nucleatum-induced chemoresistance in colorectal cancer by inhibiting miR-361-5p/sonic hedgehog signaling-regulated stemness.
    Br J Cancer. 2022 Nov 17. pii: 10.1038/s41416-022-02044.
    PubMed     Abstract available
    
    
    
81. PROPPER DJ, Gao F, Saunders MP, Sarker D, et al
    PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
    Br J Cancer. 2022 Nov 9. pii: 10.1038/s41416-022-02015.
    PubMed     Abstract available
    
    
    
82. FAULKNER LG, Howells LM, Pepper C, Shaw JA, et al
    The utility of ctDNA in detecting minimal residual disease following curative surgery in colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2022 Nov 8. pii: 10.1038/s41416-022-02017.
    PubMed     Abstract available
    
    
    
83. LI SJ, Seedher T, Sharples LD, Benton SC, et al
    Impact of changes to the interscreening interval and faecal immunochemical test threshold in the national bowel cancer screening programme in England: results from the FIT pilot study.
    Br J Cancer. 2022;127:1525-1533.
    PubMed     Abstract available
    
    
    
84. CHEN KH, Hsu CL, Su YL, Yuan CT, et al
    Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02010.
    PubMed     Abstract available
    
    
    
85. OKADA Y, Peng F, Perea J, Corchete L, et al
    Genome-wide methylation profiling identifies a novel gene signature for patients with synchronous colorectal cancer.
    Br J Cancer. 2022 Nov 1. pii: 10.1038/s41416-022-02033.
    PubMed     Abstract available
    
    
    October 2022
86. BUTLER EN, Zhou CK, Curry M, McMenamin U, et al
    Testosterone therapy and cancer risks among men in the SEER-Medicare linked database.
    Br J Cancer. 2022 Oct 28. pii: 10.1038/s41416-022-02019.
    PubMed     Abstract available
    
    
    
87. MELTZER S, Negard A, Bakke KM, Hamre HM, et al
    Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer.
    Br J Cancer. 2022 Oct 13. pii: 10.1038/s41416-022-02004.
    PubMed     Abstract available
    
    
    
88. LIU Y, Zhang L, Chen X, Chen D, et al
    The novel FGFR inhibitor F1-7 induces DNA damage and cell death in colon cells.
    Br J Cancer. 2022;127:1014-1025.
    PubMed     Abstract available
    
    
    
89. JAN YH, Tan KT, Chen SJ, Yip TTC, et al
    Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing.
    Br J Cancer. 2022;127:1304-1311.
    PubMed     Abstract available
    
    
    September 2022
90. ZHANG Y, Song M, Chan AT, Meyerhardt JA, et al
    Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study.
    Br J Cancer. 2022 Sep 22. pii: 10.1038/s41416-022-01975.
    PubMed     Abstract available
    
    
    
91. ALLEN I, Hassan H, Sofianopoulou E, Eccles D, et al
    Risk of developing a second primary cancer in male breast cancer survivors: a systematic review and meta-analysis.
    Br J Cancer. 2022 Sep 17. pii: 10.1038/s41416-022-01940.
    PubMed     Abstract available
    
    
    
92. YKEMA BLM, Breekveldt ECH, Carvalho B, van Wezel T, et al
    Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors.
    Br J Cancer. 2022 Sep 10. pii: 10.1038/s41416-022-01972.
    PubMed     Abstract available
    
    
    
93. EMONS G, Auslander N, Jo P, Kitz J, et al
    Gene-expression profiles of pretreatment biopsies predict complete response of rectal cancer patients to preoperative chemoradiotherapy.
    Br J Cancer. 2022;127:766-775.
    PubMed     Abstract available
    
    
    August 2022
94. HSIEH CC, Hsu SH, Lin CY, Liaw HJ, et al
    CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer.
    Br J Cancer. 2022 Aug 23. pii: 10.1038/s41416-022-01946.
    PubMed     Abstract available
    
    
    July 2022
95. CHAKROBORTY D, Goswami S, Fan H, Frankel WL, et al
    Neuropeptide Y, a paracrine factor secreted by cancer cells, is an independent regulator of angiogenesis in colon cancer.
    Br J Cancer. 2022 Jul 28. pii: 10.1038/s41416-022-01916.
    PubMed     Abstract available
    
    
    
96. FOERSCH S, Lang-Schwarz C, Eckstein M, Geppert C, et al
    pT3 colorectal cancer revisited: a multicentric study on the histological depth of invasion in more than 1000 pT3 carcinomas-proposal for a new pT3a/pT3b subclassification.
    Br J Cancer. 2022 Jul 21. pii: 10.1038/s41416-022-01889.
    PubMed     Abstract available
    
    
    
97. RAMSAY RG, Flood M
    New insights into the unique nature of colorectal cancer peritoneal metastases-rethinking HIPEC.
    Br J Cancer. 2022 Jul 13. pii: 10.1038/s41416-022-01905.
    PubMed     Abstract available
    
    
    
98. PANG X, Xie P, Yu L, Chen H, et al
    A new magnetic resonance imaging tumour response grading scheme for locally advanced rectal cancer.
    Br J Cancer. 2022;127:268-277.
    PubMed     Abstract available
    
    
    
99. SONG M, Li S, Wang H, Hu K, et al
    MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer.
    Br J Cancer. 2022;127:249-257.
    PubMed     Abstract available
    
    
    June 2022
100. ZAMAN FY, Orchard SG, Haydon A, Zalcberg JR, et al
     Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.
     Br J Cancer. 2022 Jun 28. pii: 10.1038/s41416-022-01882.
     PubMed     Abstract available
     
     
     
101. ARORA SP, Tenner L, Sarantopoulos J, Morris J, et al
     Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC).
     Br J Cancer. 2022 Jun 23. pii: 10.1038/s41416-022-01892.
     PubMed     Abstract available
     
     
     
102. HASHIMOTO T, Takayanagi D, Yonemaru J, Naka T, et al
     Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.
     Br J Cancer. 2022 Jun 17. pii: 10.1038/s41416-022-01880.
     PubMed     Abstract available
     
     
     
103. MORETTO R, Elliott A, Rossini D, Intini R, et al
     Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
     Br J Cancer. 2022 Jun 3. pii: 10.1038/s41416-022-01852.
     PubMed     Abstract available
     
     
     
104. DI MARTINO E, Smith L, Bradley SH, Hemphill S, et al
     Incidence trends for twelve cancers in younger adults-a rapid review.
     Br J Cancer. 2022;126:1374-1386.
     PubMed     Abstract available
     
     
     
105. KLEIF J, Jorgensen LN, Hendel JW, Madsen MR, et al
     Early detection of colorectal neoplasia: application of a blood-based serological protein test on subjects undergoing population-based screening.
     Br J Cancer. 2022;126:1387-1393.
     PubMed     Abstract available
     
     
     
106. GINER-CALABUIG M, De Leon S, Wang J, Fehlmann TD, et al
     Mutational signature profiling classifies subtypes of clinically different mismatch-repair-deficient tumours with a differential immunogenic response potential.
     Br J Cancer. 2022;126:1595-1603.
     PubMed     Abstract available
     
     
     
107. LI H, van der Merwe PA, Sivakumar S
     Biomarkers of response to PD-1 pathway blockade.
     Br J Cancer. 2022;126:1663-1675.
     PubMed     Abstract available
     
     
     
108. LI Z, Wang K, Shivappa N, Hebert JR, et al
     Inflammatory potential of diet and colorectal carcinogenesis: a prospective longitudinal cohort.
     Br J Cancer. 2022;126:1735-1743.
     PubMed     Abstract available
     
     
     
109. LATACZ E, Hoppener D, Bohlok A, Leduc S, et al
     Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.
     Br J Cancer. 2022 Jun 1. pii: 10.1038/s41416-022-01859.
     PubMed     Abstract available
     
     
     May 2022
110. JUNG SH, Kim D, Park JW
     Reply to comment(s) on "Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index".
     Br J Cancer. 2022 May 31. pii: 10.1038/s41416-022-01862.
     PubMed    
     
     
     
111. XIE H, Ge Y, Shi H
     Comment on "Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index".
     Br J Cancer. 2022 May 31. pii: 10.1038/s41416-022-01861.
     PubMed    
     
     
     
112. FISCHER LE, Stintzing S, von Weikersthal LF, Modest DP, et al
     Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
     Br J Cancer. 2022 May 30. pii: 10.1038/s41416-022-01854.
     PubMed     Abstract available
     
     
     
113. KIM S, Lim Y, Kang JK, Kim HP, et al
     Dynamic changes in longitudinal circulating tumour DNA profile during metastatic colorectal cancer treatment.
     Br J Cancer. 2022 May 28. pii: 10.1038/s41416-022-01837.
     PubMed     Abstract available
     
     
     
114. UUTELA A, Osterlund E, Halonen P, Kallio R, et al
     Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study.
     Br J Cancer. 2022 May 24. pii: 10.1038/s41416-022-01858.
     PubMed     Abstract available
     
     
     
115. YU L, Guo Q, Luo Z, Wang Y, et al
     TXN inhibitor impedes radioresistance of colorectal cancer cells with decreased ALDH1L2 expression via TXN/NF-kappaB signaling pathway.
     Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01835.
     PubMed     Abstract available
     
     
     
116. SCHMID F, Dahlmann M, Rohrich H, Kobelt D, et al
     Calcium-binding protein S100P is a new target gene of MACC1, drives colorectal cancer metastasis and serves as a prognostic biomarker.
     Br J Cancer. 2022 May 21. pii: 10.1038/s41416-022-01833.
     PubMed     Abstract available
     
     
     
117. GREENE G, Griffiths R, Han J, Akbari A, et al
     Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system.
     Br J Cancer. 2022 May 2. pii: 10.1038/s41416-022-01830.
     PubMed     Abstract available
     
     
     
118. PEPPELENBOSCH MP, Janmaat VT
     Editorial on "A systematic review of microbial markers for risk prediction of colorectal neoplasia" by Yu and coauthors.
     Br J Cancer. 2022;126:1239-1240.
     PubMed     Abstract available
     
     
     
119. YU L, Zhao G, Wang L, Zhou X, et al
     A systematic review of microbial markers for risk prediction of colorectal neoplasia.
     Br J Cancer. 2022;126:1318-1328.
     PubMed     Abstract available
     
     
     
120. MESSAOUDI N, Henault D, Stephen D, Cousineau I, et al
     Prognostic implications of adaptive immune features in MMR-proficient colorectal liver metastases classified by histopathological growth patterns.
     Br J Cancer. 2022;126:1329-1338.
     PubMed     Abstract available
     
     
     April 2022
121. ELOMAA H, Ahtiainen M, Vayrynen SA, Ogino S, et al
     Prognostic significance of spatial and density analysis of T lymphocytes in colorectal cancer.
     Br J Cancer. 2022 Apr 21. pii: 10.1038/s41416-022-01822.
     PubMed     Abstract available
     
     
     
122. BUCCHI L, Mancini S, Baldacchini F, Ravaioli A, et al
     How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study.
     Br J Cancer. 2022 Apr 20. pii: 10.1038/s41416-022-01813.
     PubMed     Abstract available
     
     
     
123. VAN CUTSEM E, Danielewicz I, Saunders MP, Pfeiffer P, et al
     First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.
     Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01737.
     PubMed     Abstract available
     
     
     
124. CALLESEN LB, Hamfjord J, Boysen AK, Pallisgaard N, et al
     Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.
     Br J Cancer. 2022 Apr 19. pii: 10.1038/s41416-022-01816.
     PubMed     Abstract available
     
     
     
125. BOGIE RMM, le Clercq CMC, Voorham QJM, Cordes M, et al
     Molecular pathways in post-colonoscopy versus detected colorectal cancers: results from a nested case-control study.
     Br J Cancer. 2022;126:865-873.
     PubMed     Abstract available
     
     
     March 2022
126. SOLIS-FERNANDEZ G, Montero-Calle A, Sanchez-Martinez M, Pelaez-Garcia A, et al
     Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis.
     Br J Cancer. 2022 Mar 28. pii: 10.1038/s41416-022-01762.
     PubMed     Abstract available
     
     
     
127. STRATING E, Wassenaar E, Verhagen M, Rauwerdink P, et al
     Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by (68)Ga-FAPI-PET imaging.
     Br J Cancer. 2022 Mar 16. pii: 10.1038/s41416-022-01748.
     PubMed     Abstract available
     
     
     
128. MAURI G, Vitiello PP, Sogari A, Crisafulli G, et al
     Liquid biopsies to monitor and direct cancer treatment in colorectal cancer.
     Br J Cancer. 2022 Mar 9. pii: 10.1038/s41416-022-01769.
     PubMed     Abstract available
     
     
     
129. JUNG SH, Hao J, Shivakumar M, Nam Y, et al
     Development and validation of a novel strong prognostic index for colon cancer through a robust combination of laboratory features for systemic inflammation: a prognostic immune nutritional index.
     Br J Cancer. 2022 Mar 5. pii: 10.1038/s41416-022-01767.
     PubMed     Abstract available
     
     
     
130. LASZLO HE, Seward E, Ayling RM, Lake J, et al
     Faecal immunochemical test for patients with 'high-risk' bowel symptoms: a large prospective cohort study and updated literature review.
     Br J Cancer. 2022;126:736-743.
     PubMed     Abstract available
     
     
     
131. LARSEN SG, Goscinski MA, Dueland S, Steigen SE, et al
     Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients.
     Br J Cancer. 2022;126:726-735.
     PubMed     Abstract available
     
     
     February 2022
132. LAOUKILI J, Constantinides A, Wassenaar ECE, Elias SG, et al
     Peritoneal metastases from colorectal cancer belong to Consensus Molecular Subtype 4 and are sensitised to oxaliplatin by inhibiting reducing capacity.
     Br J Cancer. 2022 Feb 22. pii: 10.1038/s41416-022-01742.
     PubMed     Abstract available
     
     
     
133. PATEL M, Pennel KAF, Quinn JA, Hood H, et al
     Spatial expression of IKK-alpha is associated with a differential mutational landscape and survival in primary colorectal cancer.
     Br J Cancer. 2022 Feb 16. pii: 10.1038/s41416-022-01729.
     PubMed     Abstract available
     
     
     
134. HAREWOOD R, Wooldrage K, Robbins EC, Kinross J, et al
     Adenoma characteristics associated with post-polypectomy proximal colon cancer incidence: a retrospective cohort study.
     Br J Cancer. 2022 Feb 11. pii: 10.1038/s41416-022-01719.
     PubMed     Abstract available
     
     
     January 2022
135. THOMSEN MK, Pedersen L, Erichsen R, Lash TL, et al
     Risk-stratified selection to colonoscopy in FIT colorectal cancer screening: development and temporal validation of a prediction model.
     Br J Cancer. 2022 Jan 20. pii: 10.1038/s41416-022-01709.
     PubMed     Abstract available
     
     
     
136. LAL N, Chan DKH, Ng ME, Vermeulen L, et al
     Primary tumour immune response and lymph node yields in colon cancer.
     Br J Cancer. 2022 Jan 18. pii: 10.1038/s41416-022-01700.
     PubMed     Abstract available
     
     
     
137. TRAN TN, Peeters M, Hoeck S, Van Hal G, et al
     Optimizing the colorectal cancer screening programme using faecal immunochemical test (FIT) in Flanders, Belgium from the "interval cancer" perspective.
     Br J Cancer. 2022 Jan 12. pii: 10.1038/s41416-021-01694.
     PubMed     Abstract available
     
     
     
138. YCHOU M, Rivoire M, Thezenas S, Guimbaud R, et al
     Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial.
     Br J Cancer. 2022 Jan 6. pii: 10.1038/s41416-021-01644.
     PubMed     Abstract available
     
     
     December 2021
139. GUO S, Li J, Huang Z, Yue T, et al
     The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation.
     Br J Cancer. 2021 Dec 24. pii: 10.1038/s41416-021-01681.
     PubMed     Abstract available
     
     
     
140. ADIB E, El Zarif T, Nassar AH, Akl EW, et al
     CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer.
     Br J Cancer. 2021 Dec 23. pii: 10.1038/s41416-021-01673.
     PubMed     Abstract available
     
     
     
141. ELEZ E, Gomez-Espana MA, Gravalos C, Garcia-Alfonso P, et al
     Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
     Br J Cancer. 2021 Dec 22. pii: 10.1038/s41416-021-01638.
     PubMed     Abstract available
     
     
     
142. MCDOWELL R, Perrott S, Murchie P, Cardwell C, et al
     Oral antibiotic use and early-onset colorectal cancer: findings from a case-control study using a national clinical database.
     Br J Cancer. 2021 Dec 17. pii: 10.1038/s41416-021-01665.
     PubMed     Abstract available
     
     
     
143. ZHANG X, Li X, He Y, Law PJ, et al
     Phenome-wide association study (PheWAS) of colorectal cancer risk SNP effects on health outcomes in UK Biobank.
     Br J Cancer. 2021 Dec 15. pii: 10.1038/s41416-021-01655.
     PubMed     Abstract available
     
     
     
144. MATSUMOTO T, Okayama H, Nakajima S, Saito K, et al
     SH2D4A downregulation due to loss of chromosome 8p is associated with poor prognosis and low T cell infiltration in colorectal cancer.
     Br J Cancer. 2021 Dec 10. pii: 10.1038/s41416-021-01660.
     PubMed     Abstract available
     
     
     November 2021
145. MANCA P, Corallo S, Lonardi S, Fuca G, et al
     Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.
     Br J Cancer. 2021 Nov 22. pii: 10.1038/s41416-021-01591.
     PubMed     Abstract available
     
     
     
146. DASH P, Ghatak S, Topi G, Satapathy SR, et al
     High PGD2 receptor 2 levels are associated with poor prognosis in colorectal cancer patients and induce VEGF expression in colon cancer cells and migration in a zebrafish xenograft model.
     Br J Cancer. 2021 Nov 8. pii: 10.1038/s41416-021-01595.
     PubMed     Abstract available
     
     
     
147. MAJANO SB, Lyratzopoulos G, Rachet B, de Wit NJ, et al
     Do presenting symptoms, use of pre-diagnostic endoscopy and risk of emergency cancer diagnosis vary by comorbidity burden and type in patients with colorectal cancer?
     Br J Cancer. 2021 Nov 5. pii: 10.1038/s41416-021-01603.
     PubMed     Abstract available
     
     
     October 2021
148. TAKEDA T, Yokoyama Y, Takahashi H, Okuzaki D, et al
     A stem cell marker KLF5 regulates CCAT1 via three-dimensional genome structure in colorectal cancer cells.
     Br J Cancer. 2021 Oct 27. pii: 10.1038/s41416-021-01579.
     PubMed     Abstract available
     
     
     
149. OUAHOUD S, Jacobs RJ, Kodach LL, Voorneveld PW, et al
     Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4.
     Br J Cancer. 2021 Oct 26. pii: 10.1038/s41416-021-01604.
     PubMed     Abstract available
     
     
     
150. OHSHIMA K, Oi R, Okuzaki D, Motooka D, et al
     Mitochondrial matrix protein C14orf159 attenuates colorectal cancer metastasis by suppressing Wnt/beta-catenin signalling.
     Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01582.
     PubMed     Abstract available
     
     
     
151. ARAI H, Xiao Y, Millstein J, Wang J, et al
     Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
     Br J Cancer. 2021 Oct 23. pii: 10.1038/s41416-021-01592.
     PubMed     Abstract available
     
     
     
152. AASEBO K, Bruun J, Bergsland CH, Nunes L, et al
     Prognostic role of tumour-infiltrating lymphocytes and macrophages in relation to MSI, CDX2 and BRAF status: a population-based study of metastatic colorectal cancer patients.
     Br J Cancer. 2021 Oct 20. pii: 10.1038/s41416-021-01586.
     PubMed     Abstract available
     
     
     
153. KONUKIEWITZ B, Schmitt M, Silva M, Pohl J, et al
     Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification.
     Br J Cancer. 2021 Oct 6. pii: 10.1038/s41416-021-01553.
     PubMed     Abstract available
     
     
     September 2021
154. ZHANG J, Nyvang D, Ibsen DB, Olsen A, et al
     Adherence to the Danish food-based dietary guidelines and risk of colorectal cancer: a cohort study.
     Br J Cancer. 2021 Sep 30. pii: 10.1038/s41416-021-01556.
     PubMed     Abstract available
     
     
     
155. CHEN D, Bao X, Zhang R, Ding Y, et al
     Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma.
     Br J Cancer. 2021;125:994-1002.
     PubMed     Abstract available
     
     
     
156. LIU Z, Thong MSY, Doege D, Koch-Gallenkamp L, et al
     Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany.
     Br J Cancer. 2021;125:877-883.
     PubMed     Abstract available
     
     
     July 2021
157. MELTZER S, Torgunrud A, Abrahamsson H, Solbakken AM, et al
     The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer.
     Br J Cancer. 2021;125:240-246.
     PubMed     Abstract available
     
     
     June 2021
158. DIXON SW, Collard TJ, Mortensson EMH, Legge DN, et al
     5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
     Br J Cancer. 2021;124:1959-1969.
     PubMed     Abstract available
     
     
     May 2021
159. KANE AM, Liu C, Fennell LJ, McKeone DM, et al
     Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia.
     Br J Cancer. 2021;124:1820-1827.
     PubMed     Abstract available
     
     
     
160. AMADOU A, Freisling H, Jenab M, Tsilidis KK, et al
     Prevalent diabetes and risk of total, colorectal, prostate and breast cancers in an ageing population: meta-analysis of individual participant data from cohorts of the CHANCES consortium.
     Br J Cancer. 2021;124:1882-1890.
     PubMed     Abstract available
     
     
     April 2021
161. THOMSON A, Bento DFC, Scurr MJ, Smart K, et al
     Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells.
     Br J Cancer. 2021;124:1552-1555.
     PubMed     Abstract available
     
     
     March 2021
162. ARTHUR RS, Dannenberg AJ, Kim M, Rohan TE, et al
     The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
     Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-020-01210.
     PubMed     Abstract available
     
     
     
163. NIMPTSCH K, Lee DH, Zhang X, Song M, et al
     Dairy intake during adolescence and risk of colorectal adenoma later in life.
     Br J Cancer. 2021;124:1160-1168.
     PubMed     Abstract available
     
     
     February 2021
164. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
     Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
     Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Colorectal Neoplasms is free of charge.